Lite Strategy (LITS) EBT Margin Growth (1y) (2017 - 2023)
Analysis
Lite Strategy (LITS) EBT Margin Growth (1y) (2017 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 1,045.00 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -16,571.00 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -153.00 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -571.00 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 553.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 4,709.00 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1,911.00 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -2,328.00 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -801,907.00 |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | 28,953.00 |
| Jun 30, 2023 | -54,742.00 |
| Mar 31, 2023 | -4,009.00 |
| Dec 31, 2022 | 17,872.00 |
| Sep 30, 2022 | 5,589.00 |
| Jun 30, 2022 | 6,733.00 |
| Mar 31, 2022 | -2,030.00 |
| Dec 31, 2021 | -2,494.00 |
| Sep 30, 2021 | -7,059.00 |
| Jun 30, 2021 | -25,368.00 |
| Mar 31, 2021 | 76,807.00 |
| Dec 31, 2020 | 104,581.00 |
| Sep 30, 2020 | 87,141.00 |
| Jun 30, 2020 | 104,759.00 |
| Mar 31, 2020 | 356.00 |
| Dec 31, 2019 | -61,279.00 |
| Sep 30, 2019 | 90,322.00 |
| Jun 30, 2019 | 30,907.00 |
| Mar 31, 2019 | 40,057.00 |
| Dec 31, 2018 | 114,109.00 |